LEBANON, N.J. and BETHESDA, Md., June 22,
2015 /PRNewswire/ -- Celimmune LLC, a clinical
development-stage immunotherapy company focused on treating and
preventing autoimmune diseases, announced today that Dr.
Francisco Leon, CEO and Chief
Medical Officer, will provide an oral presentation on an abstract
related to the company's lead product candidate, AMG 714, at the
16th International Coeliac Disease Symposium (ICDS),
June 24, 2015, in Prague, Czech Republic.
The abstract, entitled, "Rationale for AMG 714, an anti-IL-15
mAb, in the treatment of celiac and refractory celiac disease," is
scheduled to be presented during the Novel Treatment session, on
Wednesday, June 24, 2015, from
11:00am – 12:30pm CEST.
AMG 714 is a Phase 2, anti-IL-15 monoclonal antibody that
Celimmune has licensed from Amgen (NASDAQ: AMGN) and is
developing for the treatment of diet non-responsive celiac disease
and Type II refractory celiac disease (RCD II), an in situ small
bowel T cell lymphoma. IL-15 is a molecule produced by the immune
system and intestinal cells that is considered to be a central
regulator of celiac disease and a driver of lymphoma growth in RCD
II. IL-15 has been shown to be one of the key factors in the loss
of tolerance to food antigens, and it also is believed to be
involved in Crohn's disease and other autoimmune and inflammatory
diseases.
About Celiac Disease
Celiac disease is a chronic hereditary systemic autoimmune
disease triggered by gluten consumption. Celiac disease is
characterized by damage to the lining of the small intestine,
causing gastrointestinal dysfunction and debilitating symptoms.
Nutritional malabsorption can lead to a failure to thrive in
children and anemia and osteopenia in adults. Over the course of a
lifetime, untreated or poorly managed celiac disease is often
associated with deteriorating general health, multiple serious
intestinal and extra-intestinal medical complications, and
increased morbidity and mortality. Currently approximately 1% of
Western and 0.5% of Asian populations suffer from celiac disease
and the diagnosed prevalence is expected to increase dramatically
with improved diagnostic tools and clinical awareness.
About Celimmune
Celimmune LLC, a clinical development-stage immunotherapy
company focused on treating and preventing autoimmune diseases,
began operating in February 2015 and
is headquartered in Lebanon, NJ
and Bethesda, MD. Celimmune will
initially focus its distinctive core competence in translational
medicine, immunotherapy clinical development and commercialization
on combating celiac disease and other serious autoimmune
diseases.
For more information about Celimmune, please visit
www.celimmune.com.
Celimmune Contact
|
Media
Contact
|
Ashleigh
Palmer
|
Amy S.
Wheeler
|
Celimmune
LLC
|
Tiberend Strategic
Advisors, Inc.
|
+1.908.428.9136
|
+1.646.362.5750
|
apalmer@celimmune.com
|
awheeler@tiberend.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celimmune-to-present-experimental-anti-il-15-antibody-amg-714-at-16th-international-coeliac-disease-symposium-300102370.html
SOURCE Celimmune LLC